Recombinant Human TACE/ADAM17 Protein, CF | R&D Systems 930-ADB product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human TACE/ADAM17 Protein, CF

catalog :

930-ADB

quantity :

10 ug

price :

379 USD

citations: 25

Reference
Bertran A, Khomiak D, Konopka A, Rejmak E, Bulska E, Seco J, et al. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors. Bioorg Chem. 2020;94:103365 pubmed publisher
Maekawa M, Tadaki H, Tomimoto D, Okuma C, Sano R, Ishii Y, et al. A Novel TNF-α Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-Ay Type 2 Diabetic Mice and Diabetic Peripheral Neuropathy in Type 1 Diabetic Mice. Biol Pharm Bull. 2019;42:1906-1912 pubmed publisher
Ikeda A, Shahid S, Blumberg B, Suzuki M, Bartlett J. ADAM10 is Expressed by Ameloblasts, Cleaves the RELT TNF Receptor Extracellular Domain and Facilitates Enamel Development. Sci Rep. 2019;9:14086 pubmed publisher
Vezzoli E, Caron I, Talpo F, Besusso D, Conforti P, Battaglia E, et al. Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease. J Clin Invest. 2019;130:2390-2403 pubmed publisher
Ye Y, Toczek J, Gona K, Kim H, Han J, Razavian M, et al. Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, 99mTc-labeling, and Evaluation. Sci Rep. 2018;8:11647 pubmed publisher
Yoneyama T, Gorry M, Sobo Vujanovic A, Lin Y, Vujanovic L, Gaither Davis A, et al. ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. J Cancer. 2018;9:2559-2570 pubmed publisher
Schaal J, Maretzky T, Tran D, Tran P, Tongaonkar P, Blobel C, et al. Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α-converting enzyme. J Biol Chem. 2018;293:2725-2734 pubmed publisher
Bolino A, Piguet F, Alberizzi V, Pellegatta M, Rivellini C, Guerrero Valero M, et al. Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination. EMBO Mol Med. 2016;8:1438-1454 pubmed publisher
Youn K, Park J, Lee J, Jeong W, Ho C, Jun M. The Identification of Biochanin A as a Potent and Selective ?-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor. Nutrients. 2016;8: pubmed
Capone C, Dabertrand F, Baron Menguy C, Chalaris A, Ghezali L, Domenga Denier V, et al. Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics. elife. 2016;5: pubmed publisher
Fresco V, Kern C, Mohammadi M, Twal W. Fibulin-1 Binds to Fibroblast Growth Factor 8 with High Affinity: EFFECTS ON EMBRYO SURVIVAL. J Biol Chem. 2016;291:18730-9 pubmed publisher
Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia A, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015;6:6175 pubmed publisher
Lee E, Han J, Woo M, Shin J, Park E, Kang J, et al. Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-? activation. J Immunol. 2014;193:2384-93 pubmed publisher
Lajoie L, Congy Jolivet N, Bolzec A, Gouilleux Gruart V, Sicard E, Sung H, et al. ADAM17-mediated shedding of Fc?RIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol. 2014;192:741-51 pubmed publisher
McDonald A, Dibble J, Evans E, Millhauser G. A new paradigm for enzymatic control of ?-cleavage and ?-cleavage of the prion protein. J Biol Chem. 2014;289:803-13 pubmed publisher
Hayes C, Dey D, Palavicini J, Wang H, Patkar K, Minond D, et al. Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. BMC Med. 2013;11:81 pubmed publisher
Moreira Tabaka H, Peluso J, Vonesch J, Hentsch D, Kessler P, Reimund J, et al. Unlike for human monocytes after LPS activation, release of TNF-? by THP-1 cells is produced by a TACE catalytically different from constitutive TACE. PLoS ONE. 2012;7:e34184 pubmed publisher
Gooz P, Dang Y, Higashiyama S, Twal W, Haycraft C, Gooz M. A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by ?5?1 integrin in kidney mesangial cells. PLoS ONE. 2012;7:e33350 pubmed publisher
Koenen R, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood. 2009;113:4799-809 pubmed publisher
Moss M, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart P, et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem. 2007;282:35712-21 pubmed
Canault M, Leroyer A, Peiretti F, Leseche G, Tedgui A, Bonardo B, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol. 2007;171:1713-23 pubmed
Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan Vague I, Nalbone G, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res. 2006;312:3969-80 pubmed
Nishi E, Hiraoka Y, Yoshida K, Okawa K, Kita T. Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme. J Biol Chem. 2006;281:31164-72 pubmed
Hinkle C, Sunnarborg S, Loiselle D, Parker C, Stevenson M, Russell W, et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J Biol Chem. 2004;279:24179-88 pubmed
Von Tresckow B, Kallen K, Von Strandmann E, Borchmann P, Lange H, Engert A, et al. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol. 2004;172:4324-31 pubmed

product information

brand :

R&D Systems

master code :

930-ADB

SKU :

930-ADB-010

product name :

Recombinant Human TACE/ADAM17 Protein, CF

description :

The Recombinant Human TACE/ADAM17 Protein, CF from R&D Systems is derived from Sf 21 (baculovirus). The Recombinant Human TACE/ADAM17 Protein, CF has been validated for the following applications: Enzyme Activity.

target :

TACE/ADAM17

category :

Proteins and Enzymes

unit size :

10 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in Tris, NaCl and Brij-35.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

observed molecular weight :

64 kDa, reducing conditions

theoretical molecular weight :

52 kDa

gene symbol :

ADAM17

details of functionality :

Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2 (Catalog # ES003 ). The specific activity is 500 pmol/min/µg, as measured under the described conditions.

endotoxin note :

<1.0 EU per 1 µg of the protein by the LAL method.

catalog number base :

930-ADB

accessionNumbers :

P78536.1

applications :

Enzyme Activity

source :

Spodoptera frugiperda , Sf 21 (baculovirus)-derived human TACE/ADAM17 protein Arg215-Asn671, with a C-terminal 6-His tag

2020 USD :

379

2021 USD :

379 USD

alt names :

ADAM 17, ADAM metallopeptidase domain 17, ADAM metallopeptidase domain 18, ADAM17, ADAM18, CD156b, CD156b antigen, CSVP, disintegrin and metalloproteinase domain-containing protein 17, EC 3.4.24.86, MGC71942, Snake venom-like protease, TACEcSVP, TNF-alpha convertase, TNF-alpha converting enzyme, TNF-alpha-converting enzyme, tumor necrosis factor, alpha, converting enzyme

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after reconstitution.